This article is reserved for members

Already a member?

Log In

Not a member ?

Free registration
AbbVie Says Phase 3 Interim Data Support Long-Term Efficacy, Safety of Migraine Drug MT
AbbVie Inc. Announces Late-Breaking Data At Aan Supporting Long-Term Safety and Efficacy of Atogepant (Qulipta®) for Prevention of Migraine CI
U.S. FDA declines to approve Supernus' drug-device combination for Parkinson's disease RE
Boehringer to lay off salespeople as Humira biosimilar sales lag RE
Boehringer to lay off salespeople as Humira biosimilar sales lag RE
AbbVie Flags Hit to Q1 Adjusted Earnings from R&D Expenses, Revises 2024 Outlook MT
US takes next step in Medicare drug price negotiations with pharma companies RE
Roivant's anti-inflammatory drug succeeds in mid-stage study RE
Barclays Raises AbbVie Price Target to $195 From $185, Maintains Overweight Rating MT
Deals of the day-Mergers and acquisitions RE
Sector Update: Health Care Stocks Decline Late Afternoon MT
Top Midday Gainers MT
Sector Update: Health Care Stocks Softer in Afternoon Trading MT
Top Midday News: Boeing CEO to Step Down; United Airlines to Face Tight FAA Scrutiny; Barclays Upgrades Disney to Overweight; EU Opens Probe Into Apple, Meta, and Google; China to Block Use of Intel, AMD Chips; Ericsson Announces 1,200 Job Cuts in Sweden MT
Global markets live: United Airlines, Qualcomm, Amazon, Nissan, Boeing... Our Logo
AbbVie to Acquire Landos Biopharma For About $137.5 Million; Landos Shares Jump MT
Landos Biopharma Shares Surge 178% on Takeover Deal With AbbVie DJ
AbbVie in Deal to Acquire Landos Biopharma for $137.5 Million DJ
AbbVie to Acquire Landos Biopharma for About $137.5 Million MT
AbbVie to Acquire Landos Biopharma for About $137.5 Million MT
AbbVie to buy Landos to expand pipeline of immunity-related illnesses RE
AbbVie Inc. agreed to acquire Landos Biopharma, Inc. on March 24, 2024. CI
Abbvie Insider Sold Shares Worth $3,716,757, According to a Recent SEC Filing MT
AbbVie Gets Full OK For Cancer Drug Acquired in ImmunoGen Deal DJ
AbbVie Gets US FDA's Full Approval for Ovarian Cancer Treatment MT
Chart AbbVie Inc.
More charts
AbbVie Inc. specializes in therapeutic drug research and development. Its products are intended for treating rheumatoid arthritis, psoriasis, Crohn's disease, thyroid disease, Parkinson's disease, HIV, complications of mucoviscidosis, low testosterone levels, and complications associated with chronic renal disease. Net sales are distributed geographically as follows: the United States (77.1%), Germany (2.3%), Canada (2%), Japan (1.9%), China (1.7%), France (1.4%), Spain ( 0.9%), Italy (0.9%), Australia (0.9%), Brazil (0.8%), United Kingdom (0.8%) and others (9.3%).
Calendar
Related indices
More about the company
Trading Rating
Investor Rating
ESG Refinitiv
C+
More Ratings
Sell
Consensus
Buy
Mean consensus
OUTPERFORM
Number of Analysts
29
Last Close Price
162.3 USD
Average target price
184.3 USD
Spread / Average Target
+13.54%
Consensus
  1. Stock Market
  2. Equities
  3. ABBV Stock
  4. News AbbVie Inc.
  5. AbbVie Maintains Quarterly Dividend at $1.55 Per Share, Payable May 15 to Stockholders of Record on April 15